The conundrum of personalized cancer management, drug development, and economics

Cancer Biotherapy and Radiopharmaceuticals

Volumn 22, Issue 6, 2007, Pages 719-721

  DeNardo, Gerald L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IBRITUMOMAB TIUXETAN; RITUXIMAB; TOSITUMOMAB I 131; YTTRIUM 90;

BLOOD TOXICITY; CANCER THERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG SAFETY; ECONOMIC ASPECT; EDITORIAL; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HUMAN; MOLECULAR BIOLOGY; MOLECULAR IMAGING; NONHODGKIN LYMPHOMA; PATIENT CARE; PRIORITY JOURNAL; PROTEOMICS; RADIOIMMUNOTHERAPY; RESPONSIBILITY; RISK ASSESSMENT; TECHNOLOGY;

DELIVERY OF HEALTH CARE; DRUG APPROVAL; HUMANS; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASMS; PERSONAL HEALTH SERVICES; PHARMACOGENETICS; RADIOIMMUNOTHERAPY; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; UNITED STATES;

EID: 37549024552     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.500     Document Type: Editorial

References (12)

1. Emmanouilides C, Witzig TE, Wiseman GA, et al. Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma. Cancer Biother Radiopharm 2007; 684-691.
2. DeNardo GL, Sysko VV, DeNardo SJ. Cure of incurable lymphoma. Int J Radiat Oncol Biol Phys 2006; 66:s46.
3. Gordon LI, Witzig T, Molina A, et al. Yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymph 2004;5:98.
4. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I-131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918.
5. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352(5):441.
6. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed refractory B-cell non-Hodgkin's lymphoma: Update results and long-term follow-up of the University of Michigan experience. Blood 2000;96:1259.
7. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized, controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453.
8. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002;20:3262.
9. Gomez H, Mas L, Casanova L. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte- macrophage colony-stimulating factor: Identification of two age subgroups with differing hematologic toxicity. J Clin Oncol 1998;16:2352.
10. Lipschitz DA. Age-related declines in hematopoietic reserve capacity. Semin Oncol 1995;22(Suppl. 1):3.
11. Tirelli U, Errante D, van Glabbeke M. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: Results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 1998;16:27.
12. Berenson A. Market forces cited in lymphoma drugs' disuse. New York Times, July 14, 2007; Science Times.